ロード中...
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
SIMPLE SUMMARY: Oncolytic Herpes simplex virus-1 (HSV-1) offers the dual potential of both lytic tumor-specific cell killing and inducing anti-tumor immune responses. The HSV-1 genome can be altered to enhance both components and this may be applicable for the treatment of a broad range of cancers....
保存先:
| 出版年: | Cancers (Basel) |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7760226/ https://ncbi.nlm.nih.gov/pubmed/33255871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12123514 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|